| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 10 | 2025 | 83 | 5.710 |
Why?
|
| CD8-Positive T-Lymphocytes | 21 | 2020 | 97 | 4.470 |
Why?
|
| Lymphocyte Activation | 22 | 2022 | 89 | 3.710 |
Why?
|
| Orthomyxoviridae Infections | 9 | 2025 | 22 | 3.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 21 | 2013 | 37 | 3.090 |
Why?
|
| Antibodies, Viral | 11 | 2025 | 65 | 2.600 |
Why?
|
| Dendritic Cells | 14 | 2018 | 59 | 2.540 |
Why?
|
| Vaccinia virus | 10 | 2018 | 15 | 2.350 |
Why?
|
| Lung | 9 | 2025 | 265 | 2.260 |
Why?
|
| Animals | 67 | 2025 | 7570 | 2.070 |
Why?
|
| Vaccines, Inactivated | 6 | 2020 | 39 | 1.990 |
Why?
|
| Adjuvants, Immunologic | 7 | 2020 | 54 | 1.950 |
Why?
|
| Mice | 53 | 2022 | 2511 | 1.900 |
Why?
|
| Influenza, Human | 3 | 2023 | 126 | 1.700 |
Why?
|
| Animals, Newborn | 9 | 2025 | 119 | 1.690 |
Why?
|
| Receptors, Antigen, T-Cell | 12 | 2020 | 29 | 1.650 |
Why?
|
| Respiratory Tract Infections | 6 | 2014 | 38 | 1.580 |
Why?
|
| Imidazoles | 3 | 2018 | 92 | 1.560 |
Why?
|
| Rubulavirus Infections | 6 | 2013 | 7 | 1.520 |
Why?
|
| Vaccination | 8 | 2025 | 146 | 1.450 |
Why?
|
| Virus Diseases | 5 | 2014 | 22 | 1.370 |
Why?
|
| Flagellin | 5 | 2017 | 16 | 1.300 |
Why?
|
| Antigens, CD | 5 | 2020 | 101 | 1.300 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2025 | 50 | 1.290 |
Why?
|
| Cell Differentiation | 10 | 2014 | 467 | 1.240 |
Why?
|
| Mice, Inbred C57BL | 23 | 2020 | 789 | 1.170 |
Why?
|
| Vaccinia | 5 | 2013 | 6 | 1.120 |
Why?
|
| Mice, Inbred BALB C | 25 | 2014 | 169 | 1.120 |
Why?
|
| Immunoglobulin G | 5 | 2025 | 128 | 1.070 |
Why?
|
| Signal Transduction | 7 | 2019 | 686 | 1.040 |
Why?
|
| Peptides | 10 | 2014 | 125 | 1.010 |
Why?
|
| Antigens, Viral | 7 | 2013 | 21 | 0.990 |
Why?
|
| Cytotoxicity, Immunologic | 10 | 2011 | 15 | 0.970 |
Why?
|
| Antibody Formation | 5 | 2022 | 47 | 0.950 |
Why?
|
| Primates | 4 | 2020 | 116 | 0.940 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2025 | 8 | 0.920 |
Why?
|
| Up-Regulation | 3 | 2020 | 191 | 0.910 |
Why?
|
| T-Lymphocytes | 6 | 2016 | 129 | 0.910 |
Why?
|
| Lymph Nodes | 6 | 2017 | 114 | 0.880 |
Why?
|
| Nanoparticles | 1 | 2025 | 56 | 0.870 |
Why?
|
| Streptococcus pneumoniae | 4 | 2017 | 40 | 0.860 |
Why?
|
| Influenza A virus | 4 | 2018 | 24 | 0.830 |
Why?
|
| Neuraminidase | 2 | 2020 | 10 | 0.810 |
Why?
|
| Lymphocytes | 2 | 2017 | 59 | 0.800 |
Why?
|
| Interleukin-4 | 2 | 2020 | 22 | 0.760 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 34 | 0.760 |
Why?
|
| Interferon-gamma | 5 | 2014 | 59 | 0.690 |
Why?
|
| Orthomyxoviridae | 2 | 2017 | 15 | 0.680 |
Why?
|
| Apyrase | 1 | 2020 | 2 | 0.670 |
Why?
|
| Apoptosis | 8 | 2008 | 362 | 0.670 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2014 | 23 | 0.640 |
Why?
|
| Viral Vaccines | 2 | 2014 | 12 | 0.630 |
Why?
|
| Viral Proteins | 8 | 2013 | 35 | 0.630 |
Why?
|
| Immunity, Innate | 3 | 2018 | 76 | 0.590 |
Why?
|
| Vaccines, Conjugate | 1 | 2018 | 17 | 0.560 |
Why?
|
| Immunity, Cellular | 3 | 2014 | 20 | 0.560 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 77 | 0.530 |
Why?
|
| Infant, Newborn | 4 | 2023 | 694 | 0.500 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 475 | 0.490 |
Why?
|
| Immunologic Memory | 3 | 2012 | 33 | 0.480 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 5 | 0.460 |
Why?
|
| Aging | 2 | 2020 | 938 | 0.460 |
Why?
|
| Antigen Presentation | 3 | 2008 | 9 | 0.450 |
Why?
|
| Viruses | 1 | 2014 | 4 | 0.450 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2014 | 12 | 0.440 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 17 | 0.440 |
Why?
|
| Th2 Cells | 1 | 2014 | 9 | 0.440 |
Why?
|
| Viral Load | 3 | 2025 | 73 | 0.430 |
Why?
|
| Host-Pathogen Interactions | 2 | 2013 | 25 | 0.430 |
Why?
|
| Th1 Cells | 1 | 2014 | 25 | 0.430 |
Why?
|
| Integrin alpha Chains | 2 | 2012 | 3 | 0.430 |
Why?
|
| Interferon Type I | 2 | 2013 | 11 | 0.430 |
Why?
|
| Respirovirus | 3 | 2003 | 3 | 0.420 |
Why?
|
| Paramyxoviridae | 1 | 2013 | 2 | 0.420 |
Why?
|
| Paramyxoviridae Infections | 1 | 2013 | 2 | 0.420 |
Why?
|
| Phosphoproteins | 5 | 2006 | 48 | 0.410 |
Why?
|
| Female | 17 | 2025 | 20247 | 0.410 |
Why?
|
| Spleen | 6 | 2012 | 85 | 0.400 |
Why?
|
| Lymphocytic choriomeningitis virus | 2 | 2012 | 22 | 0.400 |
Why?
|
| Toll-Like Receptors | 2 | 2012 | 24 | 0.400 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2013 | 18 | 0.400 |
Why?
|
| Humans | 26 | 2025 | 32777 | 0.390 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 1012 | 0.380 |
Why?
|
| Dose-Response Relationship, Immunologic | 5 | 2011 | 17 | 0.370 |
Why?
|
| Adoptive Transfer | 4 | 2014 | 27 | 0.370 |
Why?
|
| Membrane Glycoproteins | 3 | 2010 | 98 | 0.370 |
Why?
|
| Antibodies, Neutralizing | 2 | 2025 | 21 | 0.360 |
Why?
|
| Cell Line | 11 | 2007 | 433 | 0.350 |
Why?
|
| Poxviridae Infections | 1 | 2010 | 1 | 0.330 |
Why?
|
| Mice, Transgenic | 5 | 2014 | 258 | 0.330 |
Why?
|
| Interleukin-10 | 1 | 2010 | 30 | 0.330 |
Why?
|
| Antigens | 5 | 2007 | 31 | 0.320 |
Why?
|
| Calcium Signaling | 1 | 2010 | 46 | 0.310 |
Why?
|
| Calcium Channels | 1 | 2010 | 61 | 0.310 |
Why?
|
| Calcium | 2 | 2017 | 323 | 0.300 |
Why?
|
| Antibody Affinity | 2 | 2007 | 2 | 0.300 |
Why?
|
| Hemagglutinins | 2 | 2023 | 5 | 0.290 |
Why?
|
| Adaptive Immunity | 2 | 2018 | 16 | 0.280 |
Why?
|
| Organ Specificity | 2 | 2020 | 80 | 0.270 |
Why?
|
| Lung Diseases | 1 | 2007 | 48 | 0.270 |
Why?
|
| Membrane Microdomains | 2 | 2004 | 21 | 0.260 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 8 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 59 | 0.250 |
Why?
|
| Macrophages | 2 | 2012 | 194 | 0.250 |
Why?
|
| Infant | 2 | 2023 | 1081 | 0.240 |
Why?
|
| Otitis Media | 2 | 2017 | 23 | 0.240 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 13 | 0.240 |
Why?
|
| Phagocytosis | 1 | 2025 | 17 | 0.230 |
Why?
|
| Ovalbumin | 2 | 2002 | 3 | 0.230 |
Why?
|
| Flow Cytometry | 6 | 2012 | 186 | 0.230 |
Why?
|
| Ferritins | 1 | 2025 | 48 | 0.230 |
Why?
|
| Cells, Cultured | 7 | 2010 | 820 | 0.220 |
Why?
|
| Immunization | 4 | 2010 | 33 | 0.220 |
Why?
|
| H-2 Antigens | 3 | 1993 | 7 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 55 | 0.210 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2013 | 9 | 0.200 |
Why?
|
| Complement Activation | 2 | 2013 | 8 | 0.200 |
Why?
|
| Respirovirus Infections | 1 | 2003 | 2 | 0.200 |
Why?
|
| Cytokines | 3 | 2010 | 247 | 0.200 |
Why?
|
| Melanoma, Experimental | 1 | 2022 | 11 | 0.190 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2016 | 9 | 0.190 |
Why?
|
| Interleukin-12 | 3 | 2013 | 28 | 0.190 |
Why?
|
| Protein Binding | 3 | 2013 | 200 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2014 | 213 | 0.180 |
Why?
|
| Peptide Fragments | 3 | 2007 | 403 | 0.170 |
Why?
|
| Health Personnel | 1 | 2022 | 129 | 0.170 |
Why?
|
| Cell Movement | 2 | 2012 | 171 | 0.170 |
Why?
|
| Melanoma | 1 | 2022 | 165 | 0.170 |
Why?
|
| Neoplasms | 2 | 2005 | 760 | 0.160 |
Why?
|
| Autocrine Communication | 1 | 2020 | 6 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2001 | 32 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2016 | 453 | 0.160 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 46 | 0.160 |
Why?
|
| Pregnancy | 1 | 2023 | 981 | 0.160 |
Why?
|
| Molecular Sequence Data | 8 | 1996 | 352 | 0.150 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2013 | 3 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| Amino Acid Sequence | 7 | 1996 | 282 | 0.150 |
Why?
|
| Major Histocompatibility Complex | 1 | 1998 | 16 | 0.150 |
Why?
|
| Receptors, LDL | 2 | 2016 | 66 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2016 | 788 | 0.140 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 24 | 0.140 |
Why?
|
| Leukocytes | 2 | 2016 | 57 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2010 | 498 | 0.140 |
Why?
|
| Sirtuin 1 | 1 | 2018 | 37 | 0.140 |
Why?
|
| Immune Tolerance | 1 | 2018 | 70 | 0.140 |
Why?
|
| Cell Death | 2 | 2017 | 71 | 0.140 |
Why?
|
| Epitopes | 3 | 2005 | 24 | 0.130 |
Why?
|
| Nitrites | 1 | 2017 | 22 | 0.130 |
Why?
|
| Symbiosis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Biofilms | 1 | 2017 | 23 | 0.130 |
Why?
|
| Hemolysis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 46 | 0.130 |
Why?
|
| Models, Molecular | 2 | 2013 | 186 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 85 | 0.130 |
Why?
|
| Sepsis | 1 | 2018 | 165 | 0.130 |
Why?
|
| Viral Structural Proteins | 2 | 2006 | 7 | 0.130 |
Why?
|
| Antigen-Presenting Cells | 2 | 2012 | 6 | 0.130 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2016 | 5 | 0.130 |
Why?
|
| HIV Antigens | 1 | 1996 | 1 | 0.120 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1996 | 1 | 0.120 |
Why?
|
| HLA-A2 Antigen | 1 | 1996 | 5 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2012 | 103 | 0.120 |
Why?
|
| Gene Products, env | 1 | 1996 | 2 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1996 | 11 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 84 | 0.120 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2016 | 57 | 0.120 |
Why?
|
| HIV-1 | 1 | 1996 | 45 | 0.120 |
Why?
|
| Aorta | 2 | 2016 | 127 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 152 | 0.120 |
Why?
|
| Cell Survival | 3 | 2006 | 280 | 0.120 |
Why?
|
| Caspase 3 | 2 | 2013 | 38 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2006 | 30 | 0.110 |
Why?
|
| Nose | 1 | 2014 | 12 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2014 | 29 | 0.110 |
Why?
|
| Gene Expression | 3 | 2014 | 334 | 0.110 |
Why?
|
| Time Factors | 3 | 2012 | 2180 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2014 | 32 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2014 | 26 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2013 | 33 | 0.100 |
Why?
|
| Complement Inactivator Proteins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 7 | 0.100 |
Why?
|
| Genome, Viral | 1 | 2013 | 10 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 49 | 0.100 |
Why?
|
| Virus Replication | 1 | 2013 | 42 | 0.100 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2013 | 1 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 486 | 0.100 |
Why?
|
| STAT5 Transcription Factor | 1 | 2013 | 4 | 0.100 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 22 | 0.100 |
Why?
|
| Recombination, Genetic | 3 | 2008 | 23 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 72 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2013 | 602 | 0.100 |
Why?
|
| Pinocytosis | 1 | 2012 | 2 | 0.100 |
Why?
|
| Caspases | 4 | 2006 | 36 | 0.100 |
Why?
|
| Mumps virus | 1 | 2012 | 2 | 0.100 |
Why?
|
| Clone Cells | 3 | 2007 | 35 | 0.100 |
Why?
|
| Vesiculovirus | 1 | 2012 | 4 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2012 | 22 | 0.090 |
Why?
|
| Plant Oils | 1 | 2012 | 17 | 0.090 |
Why?
|
| Kinetics | 1 | 2012 | 205 | 0.090 |
Why?
|
| Aortic Diseases | 1 | 2012 | 62 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2010 | 287 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 881 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 9 | 0.090 |
Why?
|
| Antigens, Bacterial | 1 | 2011 | 16 | 0.090 |
Why?
|
| Monocytes | 1 | 2012 | 130 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 2022 | 155 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 160 | 0.090 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2011 | 14 | 0.090 |
Why?
|
| Mice, Inbred DBA | 2 | 2003 | 39 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2012 | 187 | 0.080 |
Why?
|
| RNA-Binding Proteins | 3 | 2006 | 69 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2003 | 59 | 0.080 |
Why?
|
| Male | 4 | 2022 | 19622 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 5 | 0.080 |
Why?
|
| Electrophysiology | 1 | 2010 | 72 | 0.080 |
Why?
|
| Protein Transport | 1 | 2010 | 72 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 255 | 0.080 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Models, Biological | 1 | 2011 | 391 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2008 | 16 | 0.070 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 46 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 835 | 0.070 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Macrophage Activation | 1 | 2007 | 11 | 0.070 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 43 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 83 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2006 | 114 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2006 | 129 | 0.060 |
Why?
|
| Interferon-beta | 1 | 2005 | 18 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 88 | 0.060 |
Why?
|
| Viral Matrix Proteins | 1 | 2005 | 9 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 27 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 22 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2005 | 70 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2005 | 18 | 0.060 |
Why?
|
| Weight Loss | 1 | 2008 | 457 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2002 | 51 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 123 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 493 | 0.050 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2003 | 6 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 2 | 0.050 |
Why?
|
| Mediastinum | 1 | 2003 | 14 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2003 | 11 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 31 | 0.050 |
Why?
|
| Thrombospondin 1 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cysticercosis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Taenia | 1 | 2002 | 1 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2017 | 133 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2002 | 80 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 71 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2001 | 16 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 142 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 779 | 0.040 |
Why?
|
| Age Factors | 1 | 2022 | 1197 | 0.040 |
Why?
|
| North Carolina | 1 | 2022 | 1545 | 0.030 |
Why?
|
| Platelet Adhesiveness | 1 | 2017 | 14 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2017 | 6 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2017 | 18 | 0.030 |
Why?
|
| Helminth Proteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 1997 | 7 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1997 | 5 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2017 | 40 | 0.030 |
Why?
|
| Exocytosis | 1 | 1997 | 10 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2016 | 61 | 0.030 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2006 | 4 | 0.030 |
Why?
|
| Lymphocyte Transfusion | 1 | 1996 | 1 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1996 | 24 | 0.030 |
Why?
|
| Mice, SCID | 1 | 1996 | 71 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1996 | 85 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 60 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1996 | 61 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 253 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 2730 | 0.030 |
Why?
|
| Carrier State | 1 | 2014 | 23 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 154 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1993 | 49 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1993 | 31 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 1993 | 96 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 1993 | 10 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 536 | 0.020 |
Why?
|
| Phenotype | 2 | 2006 | 638 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1993 | 39 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2012 | 3 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2012 | 6 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2012 | 11 | 0.020 |
Why?
|
| Virus Assembly | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cricetulus | 1 | 2012 | 13 | 0.020 |
Why?
|
| CHO Cells | 1 | 2012 | 24 | 0.020 |
Why?
|
| Echium | 1 | 2012 | 11 | 0.020 |
Why?
|
| Cricetinae | 1 | 2012 | 39 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2012 | 36 | 0.020 |
Why?
|
| Graft Survival | 1 | 1993 | 313 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2012 | 87 | 0.020 |
Why?
|
| Neutrophils | 1 | 2012 | 110 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 102 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2008 | 240 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1990 | 88 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1990 | 100 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 10533 | 0.020 |
Why?
|
| Adult | 1 | 2022 | 9545 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 247 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 12114 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 65 | 0.020 |
Why?
|
| Hela Cells | 1 | 2006 | 80 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 6 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2006 | 12 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 163 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 91 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 52 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 47 | 0.020 |
Why?
|
| Indoles | 1 | 2006 | 56 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2006 | 290 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 497 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 726 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 247 | 0.010 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2003 | 1 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 2003 | 6 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 94 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 2002 | 1 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2001 | 6 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 134 | 0.010 |
Why?
|
| Proteins | 1 | 2001 | 142 | 0.010 |
Why?
|
| HIV Infections | 1 | 2003 | 424 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1997 | 4 | 0.010 |
Why?
|
| Methods | 1 | 1997 | 11 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1997 | 6 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1997 | 6 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1997 | 10 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 78 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 199 | 0.010 |
Why?
|
| Alleles | 1 | 1996 | 253 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1993 | 11 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1993 | 151 | 0.010 |
Why?
|
| Haplotypes | 1 | 1993 | 220 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1993 | 1 | 0.010 |
Why?
|
| Growth Substances | 1 | 1990 | 7 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1990 | 8 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1990 | 24 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1990 | 11 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1990 | 26 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1990 | 28 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 73 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1990 | 120 | 0.000 |
Why?
|